Novo Nordisk A/S
Experts hesitate on weight loss ETFs amid the obesity drug boom
There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space. Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of two […]
Read More
Eli Lilly taps Amazon Pharmacy to help deliver weight loss drug Zepbound, other medicines to patients
Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients’ homes through the drugmaker’s new direct-to-consumer program. Starting Wednesday, […]
Read More
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The Food and Drug Administration approved Novo Nordisk‘s blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart disease, the […]
Read More
Novo Nordisk CEO says experimental weight loss pill could become a best in class drug
Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company’s experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and […]
Read More
Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
The logo of Danish pharmaceutical company is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017. Liselotte Sabroe | AFP | Getty Images Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday, after fresh early trial data showed positive results for its new experimental weight loss pill. […]
Read More
Cigna launches effort to cap employer insurance plan spending on weight loss drugs
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Cigna on Thursday unveiled a new effort to expand insurance coverage for weight loss drugs by limiting how much health plans and employers spend on the highly popular treatments each year. […]
Read More
Novo Nordisk shares soar 5% on promising fat reduction demo final results Eli Lilly dips
Jonathan Raa | Nurphoto | Getty Photos Novo Nordisk shares climbed 5% on Thursday early morning, in accordance to LSEG details, hitting a fresh new record highs right after the Danish pharmaceutical big claimed positive early demo data for a new experimental fat loss drug. The company told an investor assembly that the Section I […]
Read More
Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial
This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France. Sebastien Bozon | Afp | Getty Images Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released […]
Read More
Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the end […]
Read More
Europe is obtaining its worst earnings period considering the fact that the onset of Covid — with small hope of a brief turnaround
Arc of Triomphe Paris, Champs-Elysees France at evening vichie81 / iStock / Getty Visuals In addition LONDON — All over a 50 percent of European firms missed earnings expectations in the latest reporting season despite presently minimal expectations, analysts advised CNBC, who predicted that the location will proceed to struggle amid large desire charges. As […]
Read More